IPO Databook: Exegenesis Bio (HK) - Aug 2026

113 Views30 Aug 2026 10:18

SUMMARY

Exegenesis Bio Inc. is a biopharmaceutical company developing gene therapies for neurological and ophthalmic diseases, established in 2019. It seeks to list on the Main Board under Chapter 18A with.
Two core products and one key product are internally developed. EXG102-031 completed Phase IIa 52-week follow-up in May 2026. EXG001-307 completed Phase I/II.
Revenue was RMB1,299 in 2025, with a loss for the year of RMB(826,902). Net liabilities were RMB(2,649,112) as of June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream